Poseida Therapeutics, Inc. (PSTX)
NASDAQ: PSTX · IEX Real-Time Price · USD
3.190
+0.110 (3.57%)
At close: Mar 28, 2024, 4:00 PM
3.180
-0.010 (-0.31%)
After-hours: Mar 28, 2024, 7:40 PM EDT

Poseida Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Year 202320222021202020192018
Revenue
64.7130.4931.24000
Revenue Growth (YoY)
-50.42%317.73%----
Gross Profit
64.7130.4931.24000
Selling, General & Admin
37.4437.5435.9223.0318.469.67
Research & Development
156.77152.9136.73103.5260.3930.88
Other Operating Expenses
00006.681.43
Operating Expenses
194.21190.44172.65126.5585.5341.99
Operating Income
-129.5-59.95-141.41-126.55-85.53-41.99
Interest Expense / Income
8.676.373.363.513.551.8
Other Expense / Income
-14.85-2.86-19.8-0.28-2.560.82
Pretax Income
-123.32-63.46-124.97-129.78-86.53-44.61
Income Tax
0.110.54000-0.2
Net Income
-123.43-64-124.97-129.78-86.53-44.4
Shares Outstanding (Basic)
907262361312
Shares Outstanding (Diluted)
907262361312
Shares Change
25.34%15.61%72.89%185.27%3.57%-
EPS (Basic)
-1.37-0.89-2.01-3.61-6.86-3.64
EPS (Diluted)
-1.37-0.89-2.01-3.61-6.86-3.64
Free Cash Flow
-95.23-30.68-105.16-130.24-69.67-39.3
Free Cash Flow Per Share
-1.06-0.43-1.69-3.62-5.52-3.23
Gross Margin
100.00%100.00%100.00%---
Operating Margin
-200.15%-45.94%-452.69%---
Profit Margin
-190.76%-49.05%-400.07%---
Free Cash Flow Margin
-147.18%-23.51%-336.64%---
EBITDA
-109.04-51.92-117.06-123.68-81.78-42.12
EBITDA Margin
-168.52%-39.78%-374.75%---
Depreciation & Amortization
5.615.174.552.591.190.69
EBIT
-114.65-57.09-121.62-126.27-82.97-42.81
EBIT Margin
-177.20%-43.75%-389.32%---
Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).